{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:53:27Z","timestamp":1791122007834,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":2540,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1093\/annonc\/mds200","type":"journal-article","created":{"date-parts":[[2012,8,4]],"date-time":"2012-08-04T00:32:20Z","timestamp":1344040340000},"page":"3007-3016","source":"Crossref","is-referenced-by-count":77,"title":["Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"M.S.N.","family":"Mohd Sharial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Crown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.T.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds200_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mds200_bb0015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00432-011-0976-2","article-title":"Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen","volume":"137","author":"Moon","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/annonc\/mdl016","article-title":"Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status","volume":"17","author":"Dowsett","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds200_bb0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1524-4741.2009.00822.x","article-title":"Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999\u20132004","volume":"15","author":"Parise","year":"2009","journal-title":"Breast J"},{"key":"10.1093\/annonc\/mds200_bb0030","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2001.19.14.3376","article-title":"Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients","volume":"19","author":"Knoop","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10354-010-0838-6","article-title":"Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment","volume":"160","author":"Hubalek","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"10.1093\/annonc\/mds200_bb0040","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1158\/0008-5472.CAN-04-1945","article-title":"Prognostic relevance of gene amplifications and coamplifications in breast cancer","volume":"64","author":"Al-Kuraya","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0045","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1200\/JCO.2007.15.8659","article-title":"Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0050","first-page":"2865","article-title":"Brain metastases in patients with advanced breast cancer","volume":"27","author":"Sanna","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mds200_bb0055","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2009.06.027","article-title":"Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases","volume":"45","author":"Heitz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds200_bb0060","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.25771","article-title":"Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds200_bb0065","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mds200_bb0070","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Aebi","year":"2010","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mds200_bb0075","doi-asserted-by":"crossref","first-page":"v15","DOI":"10.1093\/annonc\/mdq160","article-title":"Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Cardoso","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds200_bb0080","series-title":"NCCN Clinical Practice Guidelines in Oncology\u2122: Breast Cancer","author":"National Comprehensive Cancer Network","year":"2011"},{"key":"10.1093\/annonc\/mds200_bb0085","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mds200_bb0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/CAD.0b013e32834120aa","article-title":"Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials","volume":"22","author":"Petrelli","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mds200_bb0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1634\/theoncologist.2008-0001","article-title":"Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dahabreh","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds200_bb0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds200_bb0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00280-008-0737-3","article-title":"Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab","volume":"63","author":"Montagna","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mds200_bb0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10147-008-0797-8","article-title":"Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer","volume":"14","author":"Ono","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mds200_bb0120","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to Trastuzumab in Breast Cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nm0411-416","article-title":"Trastuzumab resistance: all roads lead to SRC","volume":"17","author":"Muthuswamy","year":"2011","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mds200_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3816\/CBC.2004.n.010","article-title":"Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories","volume":"5","author":"Gelmon","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mds200_bb0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3816\/CBC.2005.n.035","article-title":"Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer","volume":"6","author":"Garcia-Saenz","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mds200_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.breast.2008.03.006","article-title":"Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies","volume":"17","author":"Fabi","year":"2008","journal-title":"Breast"},{"key":"10.1093\/annonc\/mds200_bb0145","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26\/breast international group 03\u201305 study","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/030089161009600302","article-title":"Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies","volume":"96","author":"Mannocci","year":"2010","journal-title":"Tumori"},{"key":"10.1093\/annonc\/mds200_bb0155","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds200_bb0160","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/onc.2009.337","article-title":"Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth","volume":"29","author":"Chandarlapaty","year":"2010","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mds200_bb0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds200_bb0175","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1158\/1078-0432.CCR-10-0410","article-title":"Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients","volume":"16","author":"Sperinde","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0180","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0185","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-09-3407","article-title":"Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor","volume":"16","author":"Scaltriti","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0190","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0195","first-page":"viii","article-title":"A phase 2 study of the HER2 anitbody-drug conjugate trastuzumab-DM1 (T-MD1) in patients (PTS) with HER2-positive metastatic breast cancer (MBC) previously treated with tratuzumab, lapatinib, and chemotherapy","volume":"21","author":"Krop","year":"2010","journal-title":"Ann Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0200","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0205","series-title":"Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8\u201312, San Antonio, TX","article-title":"First results of the NeoALTTO trial (BIG 01-06 \/ EGF 106903): a phase III randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer","author":"Baselga","year":"2010"},{"key":"10.1093\/annonc\/mds200_bb0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds200_bb0215","series-title":"Presented at the 34th Annual San Antonio Breast Cancer Symposium, December 6\u201310, 2011, San Antonio, TX","article-title":"Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA)","author":"Schneeweiss","year":"2011"},{"key":"10.1093\/annonc\/mds200_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds200_bb0225","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2011.37.4207","article-title":"Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mds200_bb0235","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mds200_bb0240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2325\/jbcs.13.137","article-title":"Activation of PI3K\/Akt signaling and hormone resistance in breast cancer","volume":"13","author":"Tokunaga","year":"2006","journal-title":"Breast Cancer"},{"key":"10.1093\/annonc\/mds200_bb0245","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ejca.2005.11.025","article-title":"The association between Akt activation and resistance to hormone therapy in metastatic breast cancer","volume":"42","author":"Tokunaga","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds200_bb0250","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/bcr1844","article-title":"Clinical significance of Akt and HER2\/neu overexpression in African-American and Latina women with breast cancer","volume":"10","author":"Wu","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0255","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1471-2407-11-248","article-title":"PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib","volume":"11","author":"Wang","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mds200_bb0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-011-1572-5","article-title":"Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer","volume":"128","author":"Razis","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds200_bb0265","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mds200_bb0270","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjc.6602926","article-title":"PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer","volume":"94","author":"Fujita","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds200_bb0275","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mds200_bb0280","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","article-title":"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer","volume":"177","author":"Esteva","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mds200_bb0285","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"Eichhorn","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0290","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O'Brien","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mds200_bb0295","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/annonc\/mdp304","article-title":"Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines","volume":"21","author":"Kataoka","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds200_bb0300","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.27.7814","article-title":"Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers","volume":"29","author":"Dave","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0305","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdm589","article-title":"Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1\/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells","volume":"19","author":"Vazquez-Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds200_bb0310","doi-asserted-by":"crossref","first-page":"e1000563","DOI":"10.1371\/journal.pbio.1000563","article-title":"HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer","volume":"8","author":"Gijsen","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1093\/annonc\/mds200_bb0315","doi-asserted-by":"crossref","first-page":"e9024","DOI":"10.1371\/journal.pone.0009024","article-title":"Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression","volume":"5","author":"Nencioni","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mds200_bb0320","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-010-1232-1","article-title":"The PI3 kinase\/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells","volume":"129","author":"Brunner-Kubath","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds200_bb0325","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cellsig.2010.10.011","article-title":"Compensatory effects in the PI3K\/PTEN\/AKT signaling network following receptor tyrosine kinase inhibition","volume":"23","author":"Goltsov","year":"2011","journal-title":"Cell Signal"},{"key":"10.1093\/annonc\/mds200_bb0330","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","article-title":"Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency","volume":"13","author":"Lu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0335","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1158\/1078-0432.CCR-09-1665","article-title":"Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells","volume":"15","author":"Miller","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0340","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0345","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mds200_bb0350","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1158\/1078-0432.CCR-08-2814","article-title":"Suppression of HER2\/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab","volume":"15","author":"Yao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0355","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-11-2750","article-title":"Dual mTORC1\/2 and HER2 Blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy","volume":"18","author":"Garcia-Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0360","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0365","series-title":"Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4\u20138, 2010","article-title":"Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in heavily pre-treated HER-2+ metastatic breast cancer (MBC) patients (pts): pooled data of extension cohorts of phase Ib\/II studies","author":"Jerusalem","year":"2010"},{"key":"10.1093\/annonc\/mds200_bb0370","series-title":"Presented at the American Society of Clinical Oncology Annual Meeting, June 4\u20138, 2010; Chicago, IL","article-title":"Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial","author":"Dalenc","year":"2010"},{"issue":"3","key":"10.1093\/annonc\/mds200_bb0375","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1359-6349(10)70458-4","article-title":"Trastuzumab (H) and everolimus (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib [abstract]","volume":"8","author":"Campone","year":"2010","journal-title":"Eur J Cancer."},{"key":"10.1093\/annonc\/mds200_bb0380","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","article-title":"Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer","volume":"125","author":"Jerusalem","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds200_bb0385","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0390","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0395","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0400","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","article-title":"Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data","volume":"26","author":"Tanaka","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0405","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","article-title":"Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer","volume":"91","author":"Clayton","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds200_bb0410","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds200_bb0415","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1634\/theoncologist.7-5-410","article-title":"Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer","volume":"7","author":"Jahanzeb","year":"2002","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds200_bb0420","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds200_bb0425","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/sj.bjc.6603351","article-title":"Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial","volume":"95","author":"Chan","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds200_bb0430","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/annonc\/mdj110","article-title":"A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease","volume":"17","author":"Papaldo","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds200_bb0435","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds200_bb0440","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-7-50","article-title":"Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial","volume":"7","author":"De Maio","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mds200_bb0445","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10637-008-9166-8","article-title":"Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. a prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)","volume":"27","author":"Schilling","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mds200_bb0450","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0455","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds200_bb0460","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1158\/1078-0432.CCR-11-0072","article-title":"HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab","volume":"17","author":"Modi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds200_bb0465","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-008-0201-4","article-title":"Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab","volume":"118","author":"Goldblatt","year":"2009","journal-title":"Breast Cancer Res Treat"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/12\/3007\/422313\/mds200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:54:38Z","timestamp":1625169278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419374885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":92,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0923753419374885"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds200","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}